The Advanced Medical Technology Association (AdvaMed) has released a comment on the U.S. Supreme Court's February 20 ruling on tariffs.
"[The] ruling by the Supreme Court makes clear that the [International Emergency Economic Powers Act] IEEPA cannot be used to levy broad tariffs on markets around the world," AdvaMed President and CEO Scott Whitaker noted. "With that said, we expect the administration will now pursue tariffs through other authorities to meet the President's goal of eliminating trade imbalances and incentivizing U.S. manufacturing. As an industry that is primarily U.S.-based, with trade surpluses in most major markets worldwide, we look forward to working with the President and his administration to find a way to help reach his goals of leveling the playing field, addressing foreign trade barriers, and ensuring that the U.S. continues to lead the world in medical innovation and patient care.
"As we move forward, it is essential that America's medtech companies have the certainty and stability we need to invest, innovate and supply U.S. patients with the timely, cost-effective medical technologies they need."
